Evidence map›Paper›PMID 24923303›Full record

ArticleBMC cancer2014

Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer.

Wei Song, Lingyun Hu, Wei Li, Guanjun Wang, Yan Li, Lei Yan, Ailing Li, Jiuwei Cui

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Wei Song
Lingyun Hu
Wei Li
Guanjun Wang
Yan Li
Lei Yan
Ailing LiCancer center, the First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China. liailing@hotmail.com.
Jiuwei Cui
First Hospital of Jilin University · CNJilin University · CNChinese People's Liberation Army · CNNational Center of Biomedical Analysis · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the most lethal gynecologic malignancy, but its etiology remains poorly understood. This study investigated the role of Fli-1 in ovarian carcinogenesis and disease survival.

methodsFli-1 protein expression was evaluated by immunohistochemistry in 104 primary epithelial ovarian cancer (EOC) patients with known follow-up data and 20 controls. Correlation between Fli-1 expression and clinical characteristics was evaluated with the logistic regression. Kaplan Meier analysis was used to assess the impact of Fli-1 expression on overall survival (OS) and disease-free survival (DFS). Cell proliferation and migration assay were used to explore the function of Fli-1 in ovarian cancer cells.

resultsFli-1 was expressed in 74% cases and up-regulated in EOC tissues compared with normal control tissues (p< 0.05). The high expression of Fli-1 was significantly associated with advanced tumor stage, positive lymph nodal involvement, and poor OS and DFS (p< 0.05). Further analysis showed Fli-1 is an independent prognostic factor for OS and DFS. Down-regulation of Fli-1 inhibited cell proliferation but did not affect cell migration in SKOV3 cells.

conclusionsThis study revealed that Fli-1 played an essential role in the development and progression of ovarian cancers. Its overexpression is intimately related to malignant phenotypes and poor clinical outcome, suggesting that Fli-1 is a potential prognostic marker and therapeutic molecular target in ovarian cancer.

Indexed as

Biomarkers, TumorCase-Control StudiesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMicrofilament ProteinsMiddle AgedOvarian NeoplasmsPrognosisReceptors, Cytoplasmic and NuclearSurvival AnalysisTrans-ActivatorsBiomarkers, TumorFLII protein, humanMicrofilament ProteinsReceptors, Cytoplasmic and NuclearTrans-Activators

Identifiers

PMID24923303
PMCPMC4089852
OpenAlexW1976985617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.